• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Parapsoriasis in a Middle-Aged Man

Article

A 58-year-old man presented with a 6-month history of a mildly pruritic rash of the left axilla. The patient was in good health, took no medications, and denied any other symptoms.

A 58-year-old man presented with a 6-month history of a mildly pruritic rash of the left axilla. The patient was in good health, took no medications, and denied any other symptoms.

A solitary, orange-red, slightly scaly and atrophic patch involved the axilla and adjacent skin. The differential diagnosis included tinea corporis, erythrasma, contact dermatitis, parapsoriasis, and mycosis fungoides (cutaneous T-cell lymphoma).

Dr Ted Rosen of Houston writes that a potassium hydroxide evaluation of scale scrapings from a lesion ruled out tinea corporis. Examination of the lesion with a hand-held black light failed to demonstrate the typical coral-red color seen in erythrasma. A skin biopsy disclosed flattened epidermis and a band-like dermal lymphocytic infiltrate that included atypical-appearing cells. Flow cytometry demonstrated clonality of the cells. These findings established the diagnosis of large plaque parapsoriasis. This disorder is considered a precursor of mycosis fungoides, although transformation into cutaneous lymphoma occurs in only about 15% to 20% of patients.

This patient's lesions resolved after a 10-week course of twice-weekly psoralen–UVA therapy. He returns for periodic evaluations.

© 2024 MJH Life Sciences

All rights reserved.